Underuse of anthracyclines in women with HER-2+ advanced breast cancer

Oncologist

Volumn 15, Issue 7, 2010, Pages 665-672

  Montemurro, Filippo ^a   Rossi, Valentina ^a   Nolè, Franco ^b   Redana, Stefania ^a   Donadio, Michela ^c   Martinello, Rossella ^a   Verri, Elena ^b   Valabrega, Giorgio ^a   Rocca, Maria Cossu ^b   Jacomuzzi, Maria Elena ^d   Viale, Giuseppe ^e   Sapino, Anna ^f   Aglietta, Massimo ^a  

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c MOLINETTE HOSPITAL   (Italy)

^d MAURIZIANO HOSPITAL   (Italy)

^e Division of Pathology and Laboratory Medicine   (Italy)

^f UNIVERSITY OF TURIN   (Italy)

Author keywords

Anthracycline; Breast neoplasm; HER 2; Neoplasm metastasis; Trastuzumab

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; NAVELBINE; PACLITAXEL; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER MORTALITY; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM METASTASIS; CONTROLLED STUDY; DRUG RECHALLENGE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG USE; DRUG WITHDRAWAL; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; SALVAGE THERAPY; SOFT TISSUE METASTASIS; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HEART DISEASES; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES;

EID: 77956103533     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0016     Document Type: Article

References (29)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687-1717.
2. Piccart-Gebhart MJ, Burzykowski T, Buyse M et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol 2008;26:1980-1986.
3. Buzdar AU, Legha SS, Hortobagyi GN et al. Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens. Cancer 1981;47:2798-2802.
4. Jensen BV. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer. Semin Oncol 2006;33(suppl 8):S15-S21.
5. Floyd JD, Nguyen DT, Lobins RL et al. Cardiotoxicity of cancer therapy. J Clin Oncol 2005;23:7685-7696.
6. Harris L, Batist G, Belt R et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002;94:25-36.
7. O'Brien ME, Wigler N, Inbar M et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440-449.
8. Trudeau ME, Clemons MJ, Provencher L et al. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines. J Clin Oncol 2009;27:5906-5910.
9. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
10. Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 2005;23:4265-4274.
11. Montemurro F, Valabrega G, Aglietta M. Trastuzumab-based combination therapy for breast cancer. Expert Opin Pharmacother 2004;5:81-96.
12. von Minckwitz G, du Bois A, Schmidt M et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 2009;27:1999-2006.
13. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-2743.
14. Järvinen TA, Tanner M, Rantanen V et al. Amplification and deletion of topoisomerase IIα associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000;156: 839-847.
15. Gianni L, Norton L, Wolmark N et al. Role of anthracyclines in the treatment of early breast cancer. J Clin Oncol 2009;27:4798-4808.
16. Sparano JA, Makhson AN, Semiglazov VF et al. Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer Previously treated with neoadjuvantadjuvant anthracycline therapy: Results from a randomized phase III study. J Clin Oncol 2009;27:4522-4529.
17. Montemurro F, Donadio M, Clavarezza M et al. Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumabbased therapy. The Oncologist 2006; 11:318-324.
18. Schneider JW, Chang AY, Rocco TP. Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart. Semin Oncol 2001;28(suppl 16):18-26.
19. Sawyer DB, Zuppinger C, Miller TA et al. Modulation of anthracyclineinduced myofibrillar disarray in rat ventricular myocytes by neuregulin-1β and anti-erbB2: Potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 2002;105:1551-1554.
20. Meyer D, Birchmeier C. Multiple essential functions of neuregulin in development. Nature 1995;378:386-390.
21. Pritchard KI, Shepherd LE, O'Malley FP et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006;354:2103-2111.
22. Gennari A, Sormani MP, Pronzato P et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: A pooled analysis of randomized trials. J Natl Cancer Inst 2008;100:14-20.
23. Slamon D, Eiermann W, Robert N et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 study. Cancer Res 2009; 69:77.
24. Chia S, Clemons M, Martin LA et al. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: A multicenter phase II trial. J Clin Oncol 2006;24:2773-2778.
25. Cortes J, Dicosimo S, Climent MA et al. Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: A multicenter phase I/II study. Clin Cancer Res 2009;15: 307-314.
26. Stickeler E, Klar M, Watermann D et al. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: A multicenter phase II trial. Breast Cancer Res Treat 2009; 117:591-598.
27. Rayson D, Richel D, Chia S et al. Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: Current experience and future strategies. Ann Oncol 2008;19:1530-1539.
28. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: Mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007;18:977-984.
29. Baselga J, Swain SM. Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009;9:463-475.